Ozempic remains on top in the GLP-1 drug market -- but for how long? The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (LLY 0.23%) and Novo Nordisk (NVO 1.42%). Unsurprisingly, these are also two of the most valuable healthcare companies in the world right now. They have been rivals for decades, and the growing popularity of their respective glucagon-like peptide 1 (GLP1) drugs ensu ...

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a nextgeneration weight loss therapeutic to safely and effectively reduce weight in patients w ...

SAN DIEGO, Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute. GLP-1 receptor ...

● . ● | --- | --- | |---------------------------------------------------|-------| | | | | Defence Investigates the Application of the Accum | | | Hydrogel Technology to Deliver GLP-1 in Order to | | | Increase the Treatment Efficacy of Diabetes and | | August 19, 2024 9:27 AM EDT | Source: Defence Therapeutics Inc. Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...

Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. For a top drugmaker like Eli Lilly (LLY -1.01%), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the healthcare industry. In the past couple of years, the company has obtained approvals for multiple new products, including Mounjaro for diabetes, Zepbound for weight ...

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform ("BRAIN AGE®") as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, on brain function. In a recently published study, Semaglutide, a GLP-1 receptor agonist that has been approved by the FDA and is currently marketed in vari ...

Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinf ...

Financial Data and Key Metrics Changes - The company reported year-over-year growth across all key profitability metrics in Q2 2024, including operating income, net income, distributable cash flow (DCF), and adjusted EBITDA [3] - Adjusted EBITDA was $121.1 million in Q2 2024, up from $90.4 million in Q2 2023, while net income increased to $46.1 million from $41.4 million [5] - Distributable cash flow reached $73.1 million in Q2 2024, compared to $54.8 million in the same quarter of 2023, with adjusted DCF at $74.2 million versus $53.3 million [5] - LTM distribution coverage as of June 30 was 1.8x, or 1.6x after factoring in distributions to preferred unitholders [5] Business Line Data and Key Metrics Changes - GDSO product margin increased by $22.4 million to $221.5 million, with gasoline distribution margins rising by $19.4 million to $147.3 million due to higher fuel margins [5][6] - Station operations product margin rose by $3 million to $74.2 million, reflecting successful merchandising initiatives [6] - In the Wholesale segment, product margin increased by $32.2 million to $91.9 million, driven by the acquisition of Motiva terminals and favorable market conditions [6] Market Data and Key Metrics Changes - The company expanded its geographic reach through the acquisition of 29 terminals, doubling storage capacity to 21.4 million barrels [3] - The portfolio of fueling stations and convenience store sites totaled 1,595, with an additional 64 sites operated under a joint venture [6] Company Strategy and Development Direction - The company is focused on maximizing the value from newly acquired assets and exploring opportunities for further investments in both terminal and retail businesses [3][14] - Management emphasized ongoing efforts in merchandising optimization across the entire portfolio, indicating a commitment to continuous improvement [15] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum entering the second half of 2024, aiming to execute strategic growth objectives and deliver value to unitholders [12] - The retail M&A market remains active, providing opportunities for expansion in the convenience store sector, particularly in Texas [16] Other Important Information - The Board declared a quarterly cash distribution of $0.72 per common unit, representing a 6.7% increase over the prior year [4] - Operating expenses increased by $19.6 million to $130 million, largely due to terminal acquisitions [8] Q&A Session Summary Question: Follow-up on Wholesale investments and opportunities - Management indicated that M&A activity remains active in both terminal and retail businesses, with a focus on maximizing value from existing assets [14] Question: Update on merchandising efforts across stores - Management confirmed that merchandising optimization is an ongoing effort across the entire portfolio, with continuous improvements expected [15] Question: Update on the joint venture in Houston - Management expressed optimism about the joint venture's potential for growth in the retail market, particularly in Texas [16]

Core Insights - Annovis Bio Inc. announced new preclinical data showing the synergistic effect of its lead compound, buntanetap, when combined with the GLP-1 agonist dulaglutide in a mouse model of Alzheimer's disease [1][3] Group 1: Company Overview - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease [1][7] - The company targets multiple neurotoxic proteins to improve synaptic transmission and reduce neuroinflammation, aiming to reverse neurodegeneration and restore brain function [6][7] Group 2: Research Findings - The combination of buntanetap and dulaglutide restored cognitive function beyond levels seen in healthy controls, with buntanetap alone restoring cognitive function to 100% and dulaglutide to 80% [3] - The recent data presented at the Alzheimer's Association International Conference indicated that another GLP-1 agonist, liraglutide, decreased cognitive decline in Alzheimer's patients by 18% [2] Group 3: Mechanism of Action - GLP-1 agonists, like dulaglutide, have better blood-brain barrier permeability due to their molecular structure, making them suitable for combination therapy with buntanetap [4] - Buntanetap inhibits the formation of neurotoxic proteins, which is crucial for addressing neurodegeneration in Alzheimer's and Parkinson's diseases [6] Group 4: Executive Commentary - The CEO of Annovis Bio expressed excitement over the significant amplification of dulaglutide's effects on memory and learning when combined with buntanetap, highlighting the potential for improved treatment outcomes [5]

Hims & Hers stock has been surging since May, but has its valuation gotten too rich? Healthcare stocks don't have to be making weight loss drugs to be hot buys due to the rising demand for glucagon-like peptide 1 (GLP-1) treatments. A good example of that is Hims & Hers Health (HIMS -12.85%). Up more than 140% this year, the telehealth company has been a hot buy with investors not only for its impressive growth but also for its ability to help connect patients with GLP-1 drugs. However, the company's strate ...